News Release

Brazilian and US researchers report Wolbachia-based (wMel) mosquito intervention reduces arboviral infections in Brazil

Meeting Announcement

Emory Health Sciences

THESE FINDINGS AND PRESS RELEASE ARE EMBARGOED UNTIL SATURDAY, NOV. 21, 2026 AT 9 A.M. ET

A Wolbachia-based mosquito intervention designed to curb dengue, Zika, and chikungunya —three arboviral diseases transmitted by Aedes aegypti mosquitoes — shows substantially reduced arboviral infections among school-aged children in Brazil. Findings from the EVITA dengue trial conducted in Belo Horizonte, Brazil, showed 68.6% efficacy in reducing arboviral infections among participating children. 

The results were presented on Nov. 21, 2026, at the American Society of Tropical Medicine & Hygiene annual meeting in National Harbor, MD.

The EVITA dengue (EValuate the efficacy of Wolbachia-InfecTed Aedes aegypti mosquitoes in reducing the incidence of Arboviral infection) trial is a four-year, school-based, cluster-randomized, controlled trial in Belo Horizonte, Brazil, led by an independent, multidisciplinary team of researchers from Brazil, including the Universidade Federal de Minas Gerais (UFMG), World Mosquito Program (WMP), Fiocruz, and Faculdade de Medicina de São José do Rio Preto (FAMERP) and the United States — including Emory University, Yale University, Johns Hopkins University and the University of Florida. 

The trial was designed to test whether releasing Wolbachia (wMel strain) infected Aedes aegypti mosquitoes in school catchment areas could reduce arboviral infections in children living in those communities. The study included 58 school-defined geographic clusters in Belo Horizonte, with 29 clusters assigned to receive releases of wMel mosquitoes in addition to standard vector-control measures and 29 clusters assigned to standard vector control alone (standard vector control consists of insecticidal sprays and mosquito source reduction). 

Wolbachia is a naturally occurring bacterium, that when transinfected into Aedes aegypti mosquitoes, dramatically reduces the mosquito’s ability to transmit several arboviruses such as dengue, Zika and chikungunya. Once introduced into a mosquito population, Wolbachia is passed from female mosquitoes to their offspring, allowing it to spread through the local mosquito population and become stably established over time. The trial implemented release of Wolbachia-infected mosquitoes from January 2021 through May 2022. 

“We are pleased to have developed this locally adapted strain from Belo Horizonte for the EVITA dengue trial and to achieve successful sustained establishment of the Wolbachia-infected mosquitoes for over three years,” says Luciano Moreira, PhD, of Fiocruz and the World Mosquito Program in Brazil. 

The EVITA trial was conducted in Brazil from 2020 to 2024 and enrolled 5,757 school children, ages six to 11. In 2024, Brazil experienced the largest recorded dengue outbreak in the country’s history, contributing to the largest global dengue burden ever reported and providing an important setting to evaluate the intervention under conditions of intense transmission.

Participating children provided a baseline blood sample in 2020 and were followed with annual blood collections through 2024. Samples were tested for dengue, Zika and chikungunya antibodies. 

“Conducting this study during the COVID-19 pandemic was an extraordinary challenge, particularly as schools closed just as we were beginning enrollment,” says Mauro Teixeira, MD, PhD, a professor of the Federal University of Minas Gerais (UFMG) and co-principal investigator of the trial.  He added, “We are deeply grateful to the children, their families, the schools, and the communities who supported this research. Their commitment, together with the dedication of the research team, made it possible to successfully follow this large cohort over several years and complete a study that has the potential to inform the future of arboviral disease prevention.”  

“Our findings in the EVITA trial show a 68.6% overall efficacy in reducing arboviral infection from this intervention,” says Sri Edupuganti, MD, co-principal investigator of the EVITA trial and professor in the Department of Medicine, Division of Infectious Diseases at Emory University School of Medicine. Specifically, for dengue the efficacy was 68.5% and for chikungunya it was a bit higher at 73.3%. “This means that children living in communities where Wolbachia-infected Aedes aegypti mosquitoes were established had substantially lower arboviral infection.” 

These findings provide important evidence that the Wolbachia method could become a powerful new tool for preventing dengue and other mosquito-borne diseases.

The scale of the laboratory effort was substantial. Tens of thousands of blood samples were processed and tested in the laboratory of Mauricio Nogueira, MD, PhD, at FAMERP in São José do Rio Preto, Brazil. “Processing and analyzing thousands of samples over several years required an enormous laboratory effort from our team. This rigorous work was essential to generating these results, which represent an important advance in the fight against arboviral diseases,” says Nogueira.

“The EVITA trial findings represent an important step forward in the search for sustainable, scalable approaches to protect 4 billion of the world’s population that live in regions, including parts of the US, where dengue, Zika and other Aedes aegypti mosquito-borne diseases occur,” says Albert Icksang Ko, MD, co-principal investigator of the trial and Raj and Indra Nooyi Professor of Public Health at Yale University. 

“The intervention substantially reduced dengue infections during Brazil’s largest recorded outbreak, demonstrating its potential to protect communities even under conditions of intense transmission,” adds Derek Cummings, PhD, co-principal investigator of the trial and Bloomberg Distinguished Professor at Johns Hopkins University.

The research was funded by the US National Institutes of Health and the Brazilian Ministry of Health. The study was overseen by the Infectious Diseases Clinical Research Consortium (IDCRC) and Vaccine and Treatment Evaluation Unit (VTEU) at Emory University, Atlanta, GA. The IDCRC and network of VTEUs are supported by the US National Institute of Allergy and Infectious Diseases, part of the NIH (Contracts UM1AI148576, UM1AI48684, HHSN272201300018I/75N93020F00001-17-0111.B1C1D1.0126). Total federal funding from the US NIH includes $(7,999,514), which is 83% of the funding for this research study. The remaining 17% of the research costs are financed by the Brazilian Ministry of Health in the amount of BRL 8,000,000 (~$1,383,891).

The results will be submitted for peer-review in a scientific journal.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.